Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3821
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Melanoma and Prostate Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Prostate Cancer.

    To find out more about Triple Analysis: Leukemia, Melanoma and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agenus
Alchemia
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
AngioChem
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Arca biopharma
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
BioNetWorks
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Colby
Cornerstone Pharmaceuticals
Cosmo Bioscience
Cosmo Pharmaceuticals
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
DNAVEC
Dong-A
Dongkook Pharm
ECI
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Ferring
Flamel Technologies
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Got-a-Gene
GP Pharm
Gradalis
Green Cross
GTx
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karo Bio
Karyon-CTT
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Memgen
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
Onconova
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pacific Biotech
Paladin Labs
Pantarhei Bioscience
Patrys
PBL Therapeutics
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Q Chip
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sapphire Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
SGX Pharmaceuticals
Shenogen
Shire
Sidus
Siena Biotech
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Sophiris Bio
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
to-BBB
Tokai Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
Unigene
United Biomedical
Valeant
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
VM Discovery
WntResearch
XBiotech
Xencor
Xerion
Xoma
Yamasa Corporation
YM BioSciences
York Pharma
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEB071
AEZS-108
afatinib
aflibercept
agatolimod
aldesleukin
alemtuzumab
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
amsacrine
APC-100
APO-866
APR-246
ARC-100
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
bafetinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bicalutamide
bisantrene
BMS-663513
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
Buparlisib
buserelin
Cabozantinib
carlumab
CB-10-01
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
cladribine
clofarabine
cositecan
CSF-GM
CT-011
custirsen
cytarabine ocfosfate
cytarabine, injectable
danusertib
dasatinib
daunorubicin
DCVax-prostate
decitabine
degarelix
denenicokin
denileukin diftitox
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E7449
elacytarabine
EMD-273063
endostatin
enocitabine
entinostat
enzastaurin hydrochloride
epirubicin
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
Exherin
figitumumab
flutamide
fresolimumab
fulvestrant
ganetespib
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Hi-8 MEL
histamine dihydrochloride
histrelin
idarubicin
idronoxil
imatinib mesilate
INCB-24360
inecalcitol
INSM-18
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
interleukin-2
interleukins
intetumumab
IPH-1101
ipilimumab
irosustat
ispinesib mesylate
JX-594
kahalalide F
KX2-391
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LGX818
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
lumiliximab
LY-2275796
MCS-110
MDV-3100
MDX-1379
MetXia
MGN-1601
midostaurin
mitoxantrone
MKC-1106-MT
MLN-8237
MORAb-004
Nab-docetaxel
nadroparin
nilotinib
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
ON-01910
OncoVAX
orteronel
ozarelix
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
peginterferon alfa-2b
pentostatin
perifosine
pertuzumab
pimasertib
plitidepsin
PLX-3397
poly-ICLC
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
razoxane
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rintatolimod
rituximab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
sunitinib malate
TAK-448
talminogene laherparepvec
tamibarotene
tandutinib
tasquinimod
temsirolimus
Tenarad
teniposide
tesetaxel
thalidomide
thymalfasin
tipifarnib
TOK-001
toremifene citrate
trabedersen
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vitespen
volociximab
vosaroxin
YM-155
zanolimumab
zibotentan
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Prostate Cancer.
    To find out more about Triple Analysis: Leukemia, Melanoma and Prostate Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Prostate Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Apoptosis: Promise or deception?
In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of companies interested in this field to around 40. Learn More


Biologicals in Oncology: Drug Pathway Analyzer
There are today at least 2306 biological drugs known to affect more than 269 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 674 drug targets that are included in this drug-pathway analyzing tool. No less than 607 of these have been recorded with mutations and 76 drug targets have mutations which have been causally implicated in cancer. Learn More